(0.00%) 5 213.50 points
(-0.02%) 39 020 points
(0.01%) 18 201 points
(-1.31%) $77.35
(0.32%) $2.21
(-0.49%) $2 312.80
(-0.96%) $27.28
(-0.77%) $980.80
(0.18%) $0.931
(0.44%) $10.95
(0.32%) $0.802
(0.20%) $91.62
Live Chart Being Loaded With Signals
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally...
Stats | |
---|---|
本日の出来高 | 1.17M |
平均出来高 | 828 469 |
時価総額 | 264.31B |
EPS | INR0 ( 2024-04-25 ) |
次の収益日 | ( INR1.800 ) 2024-07-24 |
Last Dividend | INR0.750 ( 2023-06-30 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 51.97 |
ATR14 | INR0.513 (0.08%) |
ボリューム 相関
Syngene International 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Syngene International 相関 - 通貨/商品
Syngene International 財務諸表
Annual | 2023 |
収益: | INR34.89B |
総利益: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2023 |
収益: | INR34.89B |
総利益: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2022 |
収益: | INR31.93B |
総利益: | INR23.33B (73.06 %) |
EPS: | INR11.59 |
FY | 2022 |
収益: | INR25.07B |
総利益: | INR17.58B (70.12 %) |
EPS: | INR9.94 |
Financial Reports:
No articles found.
Syngene International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.750 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.500 | 2016-03-17 |
Last Dividend | INR0.750 | 2023-06-30 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | INR3.25 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 2.96 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.19 | |
Div. Directional Score | 8.93 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.16% |
2019 | INR0.500 | 0.18% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0.500 | 0.08% |
2023 | INR0.750 | 0.13% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SONATSOFTW.NS | Dividend Knight | 2023-07-21 | Semi-Annually | 23 | 1.92% | |
MOLDTECH.NS | Dividend Knight | 2023-09-18 | Annually | 9 | 1.62% | |
HEG.NS | Dividend Junior | 2023-08-24 | Annually | 23 | 1.70% | |
BHARATRAS.NS | Dividend Junior | 2023-09-06 | Annually | 17 | 0.01% | |
RAMAPHO.NS | No Dividend Player | 2023-08-10 | Annually | 3 | 0.17% | |
KKCL.NS | Dividend Knight | 2023-05-11 | Semi-Annually | 19 | 1.67% | |
ENIL.NS | Dividend Junior | 2023-09-15 | Annually | 12 | 0.39% | |
ALICON.NS | Dividend Junior | 2023-09-13 | Annually | 18 | 0.25% | |
SUTLEJTEX.NS | Dividend Junior | 2023-08-18 | Annually | 18 | 1.03% | |
NDRAUTO.NS | Dividend Junior | 2023-07-12 | Annually | 4 | 0.59% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.146 | 1.500 | 7.08 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0829 | 1.200 | 7.24 | 8.68 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.712 | 0.800 | 6.44 | 5.15 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.492 | 1.500 | 8.38 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0309 | -1.500 | 9.48 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 14.26 | 1.000 | 5.83 | 5.83 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.66 | 2.00 | 4.78 | 9.56 | [0 - 30] |
freeCashFlowPerShareTTM | 15.66 | 2.00 | 2.17 | 4.34 | [0 - 20] |
debtEquityRatioTTM | 0.0446 | -1.500 | 9.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.636 | 1.000 | 2.73 | 2.73 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.193 | 1.000 | 8.14 | 8.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 3.31 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.567 | 0.800 | 9.55 | 7.64 | [0.5 - 2] |
Total Score | 11.66 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 52.44 | 1.000 | 4.80 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 15.66 | 2.00 | 4.78 | 4.34 | [0 - 30] |
dividendYielPercentageTTM | 0.113 | 1.500 | 7.18 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.66 | 2.00 | 4.78 | 9.56 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 6.34 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.180 | 1.000 | 7.99 | 0 | [0.1 - 0.5] |
Total Score | 6.19 |
Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。